Fidelity Investments’s Centessa Pharmaceuticals CNTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-6,852,047
Closed -$272M – 5596
2026
Q1
$272M Sell
6,852,047
-2,109,892
-24% -$54M 0.01% 726
2025
Q4
$224M Buy
8,961,939
+2,684,696
+43% +$68M 0.01% 822
2025
Q3
$152M Buy
6,277,243
+2,451,049
+64% +$43.6M 0.01% 972
2025
Q2
$50.3M Hold
3,826,194
– – ﹤0.01% 1396
2025
Q1
$55M Buy
3,826,194
+174,600
+5% +$2.86M ﹤0.01% 1320
2024
Q4
$61.2M Buy
3,651,594
+735,100
+25% +$12.2M ﹤0.01% 1308
2024
Q3
$46.6M Buy
2,916,494
+129,300
+5% +$1.58M ﹤0.01% 1410
2024
Q2
$25.2M Hold
2,787,194
– – ﹤0.01% 1567
2024
Q1
$31.5M Hold
2,787,194
– – ﹤0.01% 1500
2023
Q4
$22.2M Hold
2,787,194
– – ﹤0.01% 1589
2023
Q3
$18M Hold
2,787,194
– – ﹤0.01% 1622
2023
Q2
$17.3M Buy
2,787,194
+1,556,285
+126% +$7.38M ﹤0.01% 1702
2023
Q1
$4.74M Hold
1,230,909
– – ﹤0.01% 2113
2022
Q4
$3.82M Buy
1,230,909
+522,118
+74% +$1.94M ﹤0.01% 2192
2022
Q3
$2.85M Buy
708,791
+698,491
+6,781% +$3.19M ﹤0.01% 2336
2022
Q2
$50K Hold
10,300
– – ﹤0.01% 3565
2022
Q1
$92K Sell
10,300
-84,000
-89% -$766K ﹤0.01% 3477
2021
Q4
$1.06M Sell
94,300
-268,437
-74% -$3.61M ﹤0.01% 2678
2021
Q3
$6.06M Sell
362,737
-427,263
-54% -$8.84M ﹤0.01% 2302
2021
Q2
$17.5M Buy
+790,000
New +$18.6M ﹤0.01% 1893

Fidelity Investments's CNTA Position: Q2 2026 in Review

Fidelity Investments sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 6,852,047 shares — an estimated $272M sold.

Fidelity Investments first reported a position in CNTA in Q2 2021 and held it in 20 quarters. The position peaked at $272M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

  • Fidelity Investments reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Fidelity Investments sold 6,852,047 Centessa Pharmaceuticals shares in Q2 2026, an estimated $272M.
  • Fidelity Investments first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 20 quarters.
  • Fidelity Investments's Centessa Pharmaceuticals position peaked at $272M in Q1 2026.
  • 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.